{
    "nct_id": "NCT03805789",
    "official_title": "A Phase 2/3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft-versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)",
    "inclusion_criteria": "* Male or female participants, >=12 years of age (>= 18 years of age for participants at German sites only), undergoing HCT for hematological malignancies, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.\n* Planned myeloablative conditioning regimen.\n* Participants must have a related or unrelated donor as follows:\n\n  * Related donor must be a 6 / 6 match for human leukocyte antigen (HLA)-A, -B, at intermediate (or higher) resolution, and -DR beta 1 (DRB1) at high resolution using deoxyribonucleic acid (DNA)-based typing.\n  * Unrelated donor must be 7 / 8 or 8 / 8 match for HLA-A, -B, and -C at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Prior autologous or allogeneic HCT.\n* T cell depleted transplant or planned use of anti-T cell antibody therapy either ex vivo or in vivo (ie, anti thymocyte globulin [ATG], alemtuzumab) for GVHD prophylaxis.\n* Planned umbilical cord blood transplant.\n* Planned use of cyclophosphamide after HCT for GVHD prophylaxis.\n* Planned haploidentical donor.",
    "miscellaneous_criteria": ""
}